Trial Profile
A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2017
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome; Renal impairment
- Focus Pharmacokinetics
- Sponsors Novartis
- 05 Oct 2016 Status changed from recruiting to completed.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 05 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.